Hennigsdorf, Germany Clinical Trials

A listing of Hennigsdorf, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 41 clinical trials
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

To evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),

type 2 diabetes mellitus
spectral domain optical coherence tomography
Novartis Investigative Site
 (8.8 away) Contact site
  • 24 May, 2021
  • +22 other locations
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis

This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.

Deutsches Rotes Kreuz Schwesternschaft Berlin Gemeinn tzige Krankenhaus GmbH
 (8.3 away) Contact site
  • 01 Jun, 2021
  • +240 other locations
Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.

Novartis Investigative Site
 (8.8 away) Contact site
  • 19 Jun, 2021
  • +24 other locations
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam in Epilepsy

The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are receiving levetiracetam and up to 3 other anti-epileptic drugs (AEDs).

Vivantes Humboldt Klinikum
 (5.2 away) Contact site
  • 02 Jun, 2021
  • +52 other locations
Study of Efficacy Safety Tolerability Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody CFZ533 in Liver Transplant Recipients With Additional 12-month Follow-up

The purpose of this study is to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 dose regimens in liver transplant recipients.

Novartis Investigative Site
 (8.8 away) Contact site
  • 06 Apr, 2021
  • +39 other locations
A 2-part Trial to Learn More About How BAY1817080 Works How Safe it is and What the Right Dose is for Participants With Diabetic Neuropathic Pain

People suffering from diabetes often have high blood sugar levels. Over time this can affect many organs including the nerves in hands and feet and can cause a nerve pain called diabetic neuropathic pain (DNP). There are treatments for DNP but in many patients they do not reach a good …

Diabetespraxis Dr. Braun
 (9.8 away) Contact site
  • 09 Jun, 2021
  • +64 other locations
Study of Verinurad in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction

Research Site
 (8.8 away) Contact site
  • 19 Jun, 2021
  • +86 other locations
Pazopanib vs. Pazopanib Plus Gemcitabine

This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic uterine tumours.

Charit Campus Virchow-Klinikum Universit tsmedizin Berlin
 (8.8 away) Contact site
  • 28 Jan, 2021
  • +15 other locations
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

A randomized, open-label assessor blinded, multi-center, controlled phase II Trial to evaluate the efficacy of AOP2014 administered bi-weekly subcutaneously (s.c.) in preventing molecular relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).

Universit tsmedizin Berlin Charite- Campus Virchow Klinikum
 (8.8 away) Contact site
  • 25 Jan, 2021
  • +47 other locations
Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy

This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a previous therapy but which has not been effective. Patients will be treated with Ponatinib 30 mg in in this study. The …

Charit University Medicine Berlin - Medical Clinic, Department of Hematology, Oncology and Tumor Immunology
 (8.8 away) Contact site
  • 15 May, 2021
  • +9 other locations